How to Lose Weight in a Month Safely

How to lose weight in a month is a common goal, but achieving it safely requires realistic expectations and evidence-based strategies. The NHS recommends a steady rate of 0.5 to 1 kg per week, making 2 to 4 kg a realistic target over four weeks through a combination of dietary changes, increased physical activity, and behavioural support. For some people, prescribed weight management medicines may also play a role. This article outlines what is achievable, what the NHS and NICE recommend, which lifestyle changes make the greatest difference, and when medical treatment might be appropriate.

How much weight can you realistically lose in a month?

A safe, realistic target is 2 to 4 kg over one month, based on the NHS-recommended rate of 0.5 to 1 kg per week achieved through a calorie deficit and increased activity.

A realistic and safe amount of weight to lose in a month is roughly 2 to 4 kg (approximately 4 to 9 lb), based on a steady rate of 0.5 to 1 kg per week. The NHS recommends this pace as achievable through a combination of reduced calorie intake and increased physical activity, without resorting to extreme restriction.

It is worth understanding why this figure matters. Losing weight faster than this often means losing muscle mass and water rather than body fat, which can leave you feeling fatigued, nutritionally depleted, and more likely to regain weight once normal eating resumes. Very low calorie diets are a specialist option used only under clinical supervision and are not suitable for self-directed use; NICE guidance (NG246) notes they should be offered only as part of a structured programme with appropriate medical oversight.

Individual results will vary depending on starting weight, age, sex, metabolic rate, and any underlying health conditions. Someone with a higher starting body weight may lose more in the first month, partly because of fluid shifts and a larger initial calorie deficit. Conversely, people with conditions such as hypothyroidism or polycystic ovary syndrome may find progress slower and should seek personalised advice from their GP.

If you are pregnant, breastfeeding, or have a current or previous eating disorder, please speak to your GP before attempting to lose weight, as standard weight-loss approaches may not be appropriate. You should also consult your GP if you experience unexplained or rapid unintentional weight loss, as this can sometimes indicate an underlying medical condition that needs assessment.

Setting a realistic expectation at the outset is important for motivation. A month is a short window, but it is long enough to establish habits, see measurable progress, and build confidence. Focusing on sustainable behaviour change rather than a specific number on the scales tends to produce better long-term outcomes.

What does the NHS recommend for safe, steady weight loss?

The NHS recommends a 600 kcal daily deficit and at least 150 minutes of moderate aerobic activity per week, with referral to a structured programme for those with a BMI of 30 or above.

The NHS recommends aiming to lose weight at a rate of 0.5 to 1 kg per week, achieved primarily through a modest reduction in daily calorie intake combined with regular physical activity. NICE guidance (NG246) recommends a deficit of around 600 kcal per day as a practical starting point for most adults.^[8][9] The NHS 12-week weight loss plan provides structured daily calorie targets as a guide, and any significant restriction should be discussed with a GP or dietitian, particularly if you have an underlying health condition.

NHS guidance and the UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity each week, such as brisk walking, cycling, or swimming, alongside muscle-strengthening activities on two or more days.^[11][12] Physical activity supports weight loss by increasing energy expenditure, preserving lean muscle mass, and improving metabolic health, including blood glucose regulation and cardiovascular function.

For people with a body mass index (BMI) of 30 or above, or a BMI of 27.5 or above in people from South Asian, Chinese, Black African, or African-Caribbean backgrounds, referral to a structured weight management programme may be appropriate. These programmes, which may be delivered in person or digitally, typically combine dietary advice, behavioural support, and physical activity guidance over a period of several months. Access depends on local Integrated Care Board (ICB) pathways, so availability may vary by area; your GP can advise on what is available locally.

NICE guidance (NG246) also highlights the importance of addressing psychological and social factors that contribute to weight gain, including sleep quality, stress, and emotional eating.^[3][4] If you are unsure where to start, booking an appointment with your GP is a sensible first step.

Which diet and lifestyle changes make the biggest difference?

Reducing portion sizes, cutting sugary drinks and high-calorie snacks, cooking at home, and improving sleep quality consistently produce the greatest impact on weight loss.

Reducing foods high in fat, salt, and sugar and increasing consumption of vegetables, wholegrains, lean protein, and healthy fats consistently produces the most meaningful results for weight loss over a month and beyond. The NHS Eatwell Guide provides a practical framework for a balanced diet. No single diet is universally superior, but evidence supports approaches that create a sustainable calorie deficit while maintaining nutritional adequacy, such as a Mediterranean-style diet or a lower-carbohydrate diet tailored to individual preference; NICE NG246 and British Dietetic Association resources note that the best dietary approach is one a person can maintain long term.

Practical changes that tend to have the greatest impact include:

• Reducing portion sizes by using smaller plates and being mindful of second helpings

• Cutting out or significantly reducing sugary drinks, alcohol, and high-calorie snacks

• Cooking more meals at home, which gives greater control over ingredients and portion sizes

• Eating more slowly and without distractions, which supports recognition of fullness cues

• Increasing daily movement, including non-exercise activity such as walking, taking the stairs, and standing more throughout the day

Sleep is often overlooked but plays a significant role. Poor sleep disrupts appetite-regulating hormones, increasing hunger and cravings for calorie-dense foods.^[16][17] NHS guidance suggests most adults need around 6 to 9 hours of good-quality sleep per night to support overall health and weight management.^[14][15]

Behavioural strategies also matter. Keeping a food diary, setting specific and measurable goals, and identifying triggers for overeating can all improve adherence. The NHS Weight Loss Plan app, available free of charge, provides structured support and calorie tracking tools. Social support, whether from a friend, family member, or a structured group programme, is associated with better outcomes over time.

Can weight loss medicines help if diet and exercise aren't enough?

MHRA-authorised medicines such as tirzepatide, semaglutide, and liraglutide can support weight loss in eligible adults, but are recommended only alongside dietary and lifestyle changes within NICE criteria.

Weight loss medicines can be an effective addition to diet and lifestyle changes for people who have not achieved sufficient progress through those measures alone, provided they meet the clinical criteria for treatment. In the UK, medicines currently authorised by the MHRA for chronic weight management include semaglutide injection (Wegovy, at doses up to 2.4 mg weekly, with a higher 7.2 mg strength also authorised), oral semaglutide (Wegovy 25 mg tablets, authorised June 2026), liraglutide (Saxenda), tirzepatide (Mounjaro), orforglipron (Foundayo), and orlistat (available on prescription and, at a lower strength, over the counter).^[22]

These medicines work through different mechanisms. GLP-1 receptor agonists such as semaglutide and liraglutide mimic a gut hormone that slows gastric emptying, reduces appetite, and promotes a feeling of fullness. Tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors and is authorised in the UK for both type 2 diabetes management and chronic weight management.^[23][24] Common side effects across the GLP-1 and GIP receptor agonist class include nausea, vomiting, diarrhoea, and constipation, which are usually most pronounced during dose escalation and tend to improve over time. Anyone experiencing severe or persistent abdominal pain while taking any of these medicines should contact their GP promptly, as acute pancreatitis has been reported in association with this drug class.

None of the injectable or oral GLP-1 or GIP receptor agonists are recommended during pregnancy or breastfeeding. If you are planning a pregnancy, speak to your prescriber before stopping or starting any weight management medicine, as washout periods apply; the relevant UK SmPC for each product gives specific guidance. Women of childbearing potential taking tirzepatide should use a non-oral contraceptive method, or add a barrier method to their existing contraception, for four weeks after starting treatment and for four weeks after each dose increase, as tirzepatide may reduce the effectiveness of oral contraceptives during that period.

NICE recommends these medicines within specific criteria, including BMI thresholds and the presence of weight-related comorbidities; the relevant NICE technology appraisals and NG246 set out the detail. Eligibility and NHS availability are determined by local Integrated Care Boards (ICBs), so access may vary by area. Private prescribing is also available through regulated services. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a medicine may be considered if it is clinically appropriate.

Suspected side effects from any of these medicines can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Tips to help you lose weight.
2. How to lose weight.
3. Overweight and obesity management (NG246).
4. Overweight and obesity management (NG246) – Physical activity and diet chapter.
5. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity chapter.
6. Overweight and obesity management (NG246) – A guide for prescribing medicines to manage overweight and obesity.
7. TA1026: A guide for prescribing medicines to manage overweight and obesity.
8. Overweight and obesity management (NG246) – National Clinical Guideline Centre appendix (review protocols, calorie deficit evidence).
9. When the evidence about weight loss raises more questions than answers.
10. Overweight and obesity in adults.
11. Physical activity guidelines: UK Chief Medical Officers' report.
12. UK Chief Medical Officers' physical activity guidelines (full guidance).
13. Physical activity guidelines for adults aged 19 to 64.
14. Sleep problems – Every Mind Matters.
15. Insomnia.
16. Effects of acute sleep loss on leptin, ghrelin, and adiponectin.
17. A single night of sleep deprivation increases ghrelin levels and feelings of hunger.
18. Associations of short sleep duration with appetite-regulating hormones and adipokines: A systematic review and meta-analysis.
19. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
20. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
21. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
22. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide/Wegovy 25 mg tablets).
23. GLP-1 medicines for weight loss and diabetes: what you need to know.
24. Tirzepatide.
25. Women on 'skinny jabs' must use effective contraception – MHRA urges in latest guidance.
26. Tirzepatide – Drugs – BNF.
27. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.

Frequently Asked Questions